External validation, recalibration, and clinical utility of the kidney failure risk equation in patients with advanced CKD: a nationwide retrospective cohort analysis in Peru

This is a Cohort Study study (also classified as: Human Clinical Trial, Validation Study).

December 5, 2025BMC NephrologyOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

Validation of the kidney failure risk equation supports its use in clinical settings, enhancing patient risk assessment.
Key evidence shows effective recalibration can improve predictions in advanced CKD, crucial for clinical decisions.
The analysis utilizes retrospective cohort data from Peru to evaluate the equation's predictive accuracy in kidney failure risk.
Improved clinical tools may enable better risk management for patients with advanced CKD, emphasizing national relevance.

We only have this paper's title and publication details.

Retrospective cohort analysis assessed validation in advanced CKD patients, suggesting improved risk evaluation in clinical practice.

Not applicable. This study is not a clinical trial.

No takes yet. Share an insight, caveat, or question.

Coila-Paricahua et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share